1. Home
  2. MFIC vs SYRE Comparison

MFIC vs SYRE Comparison

Compare MFIC & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MFIC
  • SYRE
  • Stock Information
  • Founded
  • MFIC 2004
  • SYRE 2013
  • Country
  • MFIC United States
  • SYRE United States
  • Employees
  • MFIC N/A
  • SYRE N/A
  • Industry
  • MFIC Finance/Investors Services
  • SYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • MFIC Finance
  • SYRE Health Care
  • Exchange
  • MFIC Nasdaq
  • SYRE Nasdaq
  • Market Cap
  • MFIC 1.2B
  • SYRE 1.1B
  • IPO Year
  • MFIC 2004
  • SYRE 2016
  • Fundamental
  • Price
  • MFIC $13.13
  • SYRE $17.38
  • Analyst Decision
  • MFIC Buy
  • SYRE Buy
  • Analyst Count
  • MFIC 5
  • SYRE 5
  • Target Price
  • MFIC $13.60
  • SYRE $55.00
  • AVG Volume (30 Days)
  • MFIC 361.8K
  • SYRE 490.8K
  • Earning Date
  • MFIC 08-11-2025
  • SYRE 08-05-2025
  • Dividend Yield
  • MFIC 11.58%
  • SYRE N/A
  • EPS Growth
  • MFIC N/A
  • SYRE N/A
  • EPS
  • MFIC 1.08
  • SYRE N/A
  • Revenue
  • MFIC $324,241,000.00
  • SYRE N/A
  • Revenue This Year
  • MFIC $9.71
  • SYRE N/A
  • Revenue Next Year
  • MFIC $0.21
  • SYRE N/A
  • P/E Ratio
  • MFIC $12.18
  • SYRE N/A
  • Revenue Growth
  • MFIC 16.80
  • SYRE N/A
  • 52 Week Low
  • MFIC $10.18
  • SYRE $10.91
  • 52 Week High
  • MFIC $14.74
  • SYRE $40.26
  • Technical
  • Relative Strength Index (RSI)
  • MFIC 58.73
  • SYRE 57.01
  • Support Level
  • MFIC $12.89
  • SYRE $15.73
  • Resistance Level
  • MFIC $13.10
  • SYRE $17.42
  • Average True Range (ATR)
  • MFIC 0.21
  • SYRE 0.89
  • MACD
  • MFIC 0.03
  • SYRE 0.07
  • Stochastic Oscillator
  • MFIC 93.00
  • SYRE 86.50

About MFIC MidCap Financial Investment Corporation

MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: